FDA slaps partial clinical hold on Phase III tolebrutinib trials

30 June 2022

The US Food and Drug Administration (FDA) has placed Phase III studies of tolebrutinib in multiple sclerosis (MS) and myasthenia gravis on partial clinical hold, said French pharma major Sanofi (Euronext: SAN), whose shares were down 4.3% at 96.55 euros as trading moved towards close today.

As a result, new enrollment in the USA is paused, and participants in the USA who have been in the trial for fewer than 60 days shall suspend study drug. Importantly, US participants who have completed at least 60-days in the trial should continue treatment.

Sanofi acquired rights to the drug along with its $3.7 billion takeover of California-based Principia Biopharma in 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK